The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

NanoViricides Highlights NV-387 Potential to Combat Global Measles Outbreaks

Key Facts

1NanoViricides stated its drug candidate NV-387 could address rising measles cases globally.

2The company cited data from Bangladesh showing over 18,000 suspected measles cases in a single month.

NanoViricides (NYSE-A: NNVC) has announced that its antiviral drug candidate, NV-387, shows significant potential in treating measles as global infection rates continue to climb. The company highlighted a critical unmet need in the medical field, noting the current lack of specific approved antiviral treatments for the virus. Citing alarming data from Bangladesh, where over 18,000 suspected cases were reported in a single month, the firm emphasized the urgency of developing effective therapeutics. This move represents a strategic expansion of the company's clinical pipeline into highly contagious viral diseases. Investors are viewing this development as a positive step toward addressing high-demand healthcare markets. The market remains focused on the progression of NV-387 through clinical stages amidst rising global health concerns.